Skip to content

Clinical trials

Diabetes Mellitus, Type 1 trials in Denmark

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Country / region: Denmark Clear all

193 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20014
20025
20031
20042
20051
20064
20077
20086
20097
20102
20116
201212
20138
20149
20159
201610
20177
20183
201910
202012
202116
20227
20239
202410
202511
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed136
Recruiting16
Unknown status15
Not yet recruiting10
Terminated8
Active, not recruiting4
Withdrawn3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Steno Diabetes Center Copenhagen45
Novo Nordisk A/S24
University of Aarhus21
Hvidovre University Hospital14
Odense University Hospital11
Eli Lilly and Company5
Nordsjaellands Hospital5
Asger Lund, MD4
University Hospital, Gentofte, Copenhagen4
Aalborg University Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 1193
Diabetes Mellitus42
Hypoglycemia33
Diabetes Mellitus, Type 229
Insulin Resistance10
Diabetic Nephropathies9
Diabetes Complications7
Diabetic Neuropathies7
Albuminuria6
Cardiovascular Diseases5

Trials

Showing 1 to 25 of 193. Each trial links to its page on Pharma Observatory.

93 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.